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Abstract
Aims-To investigate the correlation be-
tween antibodies to the transforming pro-
tein E7 of human papillomavirus (HPV)
type 16 and clinicopathological indices in
women with cervical squamous car-
cinoma.
Methods-A synthetic peptide of the
HPV type 16 E7 protein (amino acids 6
to 35) was used to screen sera from
29 children, 130 women with cervical
intraepithelial neoplasia, 443 women with
cervical cancer, and 222 controls, for
antibodies against this viral antigen. Bi-
variate and multivariate analyses were
used to investigate the correlation be-
tween the serological status in the pre-
treatment sera and clinicopathological
indices (size of the lesion, histological
grade, stromal infiltration, vascular in-
vasion, and nodal spread). Survival ana-
lysis was done using the Cox regression
model for all FIGO stages and stages IB
and IIA.
Results-Cervical carcinoma patients had
a significantly higher prevalence of anti-
bodies to synthetic peptide E7\6-35 than
women with cervical intraepithelial neo-
plasia (17.7% v 7%, p<O0O5) or controls
(17-7% v 11%, p<005). Bivariate analysis
of the data on the presence of anti-
E7\6-35 antibodies in the pretreatment
sera from these patients and clinico-
pathological indices showed a significant
correlation between the presence of anti-
E7\6-35 antibodies and the size of the
lesion (p = 0.0009), histological grade (p=
0-031), and lymph node metastasis (p=
0.011). In addition, the Cox regression
model, analysing four risk factors which
can be determined before treatment,
showed a significant correlation between
the presence of anti-E7\6-35 antibodies
and a worse prognosis (p=0.003). Sur-
vival analysis revealed that both for all
FIGO stages (p=0.0005) and for stages
IB and IIA alone (p=0.0021), anti-
E7\6-35 positive patients before treat-
ment had a significantly shorter life ex-
pectancy.
Conclusions-The presence of antibodies
against E7\6-35 in pretreatment sera
from patients with cervical carcinoma
correlates with the size of the lesion,
lymph node involvement, and a worse
prognosis.
(Jr Clin Pathol 1995;48:410-414)
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Human papillomaviruses (HPV) are a group
of viruses which are associated with various
proliferative diseases in the infected epi-
thelium.' To date, more than 70 HPV types
have been reported. Some of these, among
which HPV types 6, 11, 16, and 18 are the
most common, are associated with lesions in
the anogenital tract.2 The "benign" types 6 and
11 are mainly associated with condylomata
acuminata. Ofthe oncogenic HPV types, HPV-
16 is most frequently found in cervical car-
cinomas and the viral genome is often found
integrated into the cellular genome.3 The nuc-
lear protein E7 of HPV-16 is considered to
be one of the two major proteins involved in
malignant transformation and the maintenance
ofthe transformed phenotype of cells. The viral
oncoprotein E7 is consistently transcribed in
both HPV positive cervical cancer cell lines
and cervical cancers.45
Until recently, few data were available on
the humoral immune response to HPV-16.
Jochmus-Kudielka et a16 have reported a 14-
fold higher prevalence of antibodies to HPV-
16 E7 in sera from cervical carcinoma patients
than in age and sex matched controls, when
fusion proteins were used in western blotting
assays for the screening of sera for the presence
ofHPV antigen specific antibodies. Using syn-
thetic peptides with known B cell epitopes,'-9
similar results have been obtained to those
found with western blotting by Jochmus-Ku-
dielka et al.6
To date, no data have been published con-
cerning the prevalence of antibodies against
HPV-16 E7 in sera from patients with cervical
squamous cell carcinoma in relation to tumour
indices, such as lesion size and nodal spread,
or to survival. To investigate the possible cor-
relation between the presence of antibodies
against HPV-16 E7 and tumour indices, pre-
treatment sera from cervical carcinoma patients
were tested in an enzyme linked immuno-
sorbent assay (ELISA) using a synthetic
peptide. This peptide was chosen to represent
reported major B cell epitopes of HPV-16 E7
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(aa 2-21,1o aa 1-20 and aa 10-30,7 aa 10-15,"
aa 10-14,12 and aa 10-2013).
Using bivariate and logistic regression ana-
lysis the results obtained for these cervical can-
cer patients were correlated with the size of the
lesion, histological grade, stromal infiltration,
vascular invasion, and nodal spread. In ad-
dition, anti-E7 positivity was related to survival.
Methods
SERA
The age distribution of patient and control
groups is shown in table 1. Twenty nine sera
of children between 0 5 and 9 years of age
were used to determine the cut off value. One
hundred and thirty sera from women with
different grades of cervical intraepithelial neo-
plasia (CIN) and 51 sera from patients with
squamous cell cervical carcinoma were ob-
tained from the Department of Gynaecology,
University of Amsterdam (head: Prof Dr F B
Lammes). A further 392 pretreatment sera
from women with squamous cell cervical car-
cinoma were obtained from the Department of
Obstetrics and Gynaecology, University Hos-
pital Groningen. The control group consisted
of 222 healthy women with a similar age dis-
tribution. No data on HPV DNA typing were
available. All women in the Amsterdam control
group had normal cytology and were matched
to the cancer patient group for age, sex, and
socioeconomic status. The control group for
cervical cancer patients from Groningen con-
sisted of sera sent in for routine screening for
other infectious diseases. No data on cytology
were available from the Groningen control
group.
CLINICOPATHOLOGICAL INDICES IN PATIENTS
WITH CERVICAL CARCINOMA
The staging of the 443 patients with cervical
carcinoma was in accordance with the re-
commendations of the International Fed-
eration ofGynaecology and Obstetrics (FIGO).
Clinicopathological data other than stage were
only available from 300 patients treated in
Groningen. Patients from whom blood samples
had been drawn after exconisation were ex-
cluded from the analysis. Examination of the
patients was performed under general anaes-
thesia. During this procedure, the lesion size
(largest diameter) was estimated routinely and
expressed in centimetres for the large majority
of patients.
Table 1 Age distribution ofpatient and control groups
Mean age (SD)
n (years)
Children 29 3-6 (2 5)
CIN 1-3 130 32-5 (7-9)
SCC 443 509 (15-7)
SCC Amsterdam 51 52-5 (13-0)
SCC Groningen 392 50-7 (16-0)
All controls 222 50-2 (16-3)
Controls Amsterdam 59 51-2 (12-8)
Controls Groningen 163 49-3 (17-7)
CIN=cervical intraepithelial neoplasia; SCC=squamous cell
carcinoma.
Patients with stage IB or IIA were mainly
treated by preoperative intracavitary radio-
therapy, followed by radical hysterectomy with
bilateral salpingo-oophorectomy and pelvic
lymphadenectomy four weeks later. Post-
operative whole pelvis radiotherapy was applied
if lymph node metastases or positive resection
margins, or both, were present. Patients with
stage IIB and most of the patients with stage
III were treated by radiotherapy only, ifpossible
followed by adjunctive hysterectomy. In the
remaining stage III patients and in all stage IV
patients, treatment was individualised using
combinations of radiotherapy, surgery, and
chemotherapy.
To correlate anti-E7 positivity with the histo-
pathological data in bivariate analysis, all
the available biopsy or cone material of 300
patients was carefully reviewed. Tumours were
classified into well differentiated (grade 1),
moderately differentiated (grade 2), poorly
differentiated (grade 3), or undifferentiated
(grade 4) squamous cell carcinoma, in ac-
cordance with the criteria laid down by Fer-
enczy and Winkler."4
Criteria for the assessment of the clinical
course of the disease were described pre-
viously."5 Briefly, "complete remission" (no
evidence of disease) was defined as the absence
of all tumour lesions three months after com-
pletion of treatment or during follow up. "Re-
sidual disease" existed when tumour lesions
were still known to be present after treatment.
"Progression of disease" was defined as the
appearance of new lesions, the growth of a
pelvic mass or other known tumour lesions, or
a distinct deterioration in the clinical status
of a patient with a known tumour ultimately
resulting in death. "Recurrent disease" was
used to indicate the reappearance of disease in
patients who experienced complete remission.
"Poor prognosis" is used to indicate the risk
for residual, progressive, or recurrent disease.
From 367 patients with cervical carcinoma,
consecutively admitted and treated at the de-
partment ofGynaecological Oncology in Gron-
ingen, follow up data were available. Of these
367 patients, 106 died of cancer.
SYNTHETIC PEPTIDE
The synthetic peptide, encompassing amino
acids 6-35 (PTLHEYMLDLQPETTDLY-
CYEQLNDSSEEE) of the HPV-16 E7 ORF,
was purchased from the Department of Im-
munology and Medical Microbiology, TNO
Medical Biological Laboratory, Rijswijk, The
Netherlands. The peptide was synthesised by
solid phase synthesis according to Merrifield16
on polystyrene resin (1% cross linking), using
an automated peptide synthesiser (SAM-2,
Biosearch). Synthetic peptides were purified
by chromatography on Sephadex G-15 and re-
verse phase high performance liquid chro-
matography (HPLC).
ELISA
Synthetic peptide (100 p1 per well at 5 gg/ml
in phosphate buffered saline (PBS), pH 7 2)
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was coated onto 96-well Maxisorp plates
(Nunc) for one hour at 37°C. Control wells
were treated in a similar way, with the omission
of synthetic peptide from the buffer. After six
rinses with distilled water the plates were
blocked with 1% gelatin in PBST (PBS con-
taining 0'05% Tween 20) for one hour at 37°C.
Sera were incubated in a 1:100 dilution in
PBST+ 1% gelatin for one hour at 37°C. Goat
anti-human IgG peroxidase (1:6700 in PBST,
1% gelatin, Diagnostic Centre SSDZ) was used
as a conjugate. After one hour at 37°C the
plates were washed six times (PBST), after
which substrate was added (3,3', 5,5'-te-
tramethyl-bendizine, Aldrich Chemie). After
20 min the reaction was stopped with 2N
H2SO4 and colour development read with a
Titertek Plate reader at 450 nm.
Each sample was tested in at least three
independent experiments. Sera which were
eventually scored as equivocal were tested in
at least five independent experiments. In each
experiment all sera were tested in duplicate on
peptide coated wells and control wells, and
the mean reactivity of the control wells was
subtracted from the mean reactivity of the
coated wells. A cut off value was determined
from the children's sera using the mean
absorption+ 3 times the standard deviation as
described by Krchnak et al.7 For intratest com-
parison, positive, negative, and borderline posi-
tive sera were included in each plate. For
intertest comparison, optical densities were re-
calculated into ratios by division by the cut off
value. Using the cut off values, none of the
children's sera was found positive for antibodies
against synthetic peptide E7\6-35.
STATISTICAL METHODS
The relationship between clinical stage of the
tumour and the presence of anti-HPV- 16 E7
antibodies was calculated using the Pearson X2
test to compare the frequency of the presence
of antibodies between 2 or >2 groups. The
interrelationships between anti-E7\6-35 posi-
tivity in pretreatment sera from cervical car-
cinoma patients and tumour related variables
were investigated using bivariate and logistic
regression analysis. The prognostic value of
anti-E7\6-35 and other possible risk factors
was determined in the Cox regression model.
The data used for bivariate and logistic re-
gression analysis of the Groningen patient
group included stage of disease (FIGO stage),
lesion size, tumour grade, lymph node status,
vascular invasion, depth of infiltration, and
presence of antibodies against E7 synthetic
Table 2 Prevalence of antibodies against HPV-16 E7\
6-35 in sera from patients with cervical intraepithelial
neoplasia (CIN), cervical cancer, and contrls
Anti-E7\635 positive
Mean ratio
N n % (SD)
CIN 129 9t 7-0 0-32 (082)
Cervical carcinoma 424 75 17-7 0-61 (1 11)
Controls 218 24* 11-0 0 40 (1-02)
* p<0 05, f p<0005 v cervical carcinoma patients.
Table 3 Prevalence of antibodies against HPV-16 E7\
6-35 in sera from 424 patients according to the stage of
disease
Anti-E7\6-35 positive
FIGO stage N n %
IB 203 30 14-6
II 163 30 18-4
III 39 5 12-8
IV 19 10 52-6
peptide 6-35. Differences between survival
curves were computed by means ofthe log rank
test.
Results
PREVALENCE OF ANTi-E7\6-35 ANTIBODIES IN
PATIENT GROUPS AND CONTROLS
The seroreactivity of the different groups to
synthetic peptide E7\6-35 is shown in table 2.
Twenty four sera, 19 from patients with cervical
carcinoma, one from a CIN patient, and four
from controls matched to the cervical car-
cinoma patients, did not give consistent results
on repeated testing. These sera, which gave
both low positive and high negative results,
were scored as equivocal and excluded from
statistical analyses.
With peptide E7\6-35, seroreactivity was sig-
nificantly higher in patients with invasive car-
cinoma than in the group of matched controls
(p<005), or women with CIN (p<0005). No
significant differences were found for sero-
reactivity against peptide E7\6-35 between
patients with different grades of CIN (CIN
1-3; data not shown).
PREVALENCE OF ANTI-E7\6-35 ANTIBODIES IN
DIFFERENT FIGO STAGES
Prevalence rates of antibodies against peptide
E7\6-35 in the different FIGO stages of
patients with invasive carcinoma are shown in
table 3. When seroreactivity against peptide
E7\6-35 was compared between the four FIGO
stages, a statistically significant trend of in-
creasing seropositivity with increasing stage was
obtained (X' = 6 38; df= 1; p = 0 01). Analysis
Table 4 Pretreatment sera from 300 patients with
cervical carcinoma: bivariate correlation of anti-E7\6-35
positivity with clinicopathological tumour indices
Anti-E7\6-35 pos
n/total
evaluable % pa
Lesion size
<4cm 14/116 12.1
.4cm 40/132 30 3 0-0009
Differentiation grade
1,2 35/213 16-4
3,4 24/71 33-8 0-031
Depth of stromal infiltration
<5mm 6/32 18-8
>5mm 22/87 25-3 NS
Vascular invasion
Negative 30/177 16-9
Positive 24/83 28-9 0-04
Lymph node status
Negative 22/139 15-8
Positive 16/46 34-8 0-011
a X2test.
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of the IgG content in the patients' sera did
not show a statistically significant difference
between the different FIGO stages.
CORRELATION OF ANTI-E7\6-35 IN
PRETREATMENT SERA FROM PATIENTS WITH
CERVICAL CARCINOMA WITH
CLINICOPATHOLOGICAL INDICES
We examined whether tumour associated fac-
tors are related to the E7\6-35 serum levels.
The results are shown in table 4. Before treat-
ment patients with a lesion size . 4 cm had a
significantly higher prevalence of antibodies
against E7\6-35 than patients with a lesion size
<4 cm (p = 00009). In addition, patients with
poorly or undifferentiated carcinoma or with
lymph node metastases showed a significantly
higher prevalence rate of antibodies against
E7\6-35 compared to patients with well or
moderately differentiated squamous cell car-
cinoma (p = 0031) or without lymph node
metastases (p=0 011). Finally, for patients
with vascular invasion of the tumour a sig-
nificantly higher prevalence rate of anti-E7\
6-35 was found in comparison with patients
without vascular invasion (p=0 04). In the
analysis of clinicopathological data on anti-
E7\6-35 using logistic regression analysis we
considered stage, lesion size, differentiation
grade, and presence or absence of lymph node
metastases. The analysis revealed a significant
independent effect of both a lesion size . 4 cm
and nodal spread on anti-E7\6-35 positivity
(X' 17-64; df=2; p=0 0001; sensitivity
33-3%; specificity 90 2%).
We further analysed the predictive value of
four pretreatment indices (stage, lesion size,
differentiation grade, and anti-E7\6-35 pos-
itivity) for the presence of lymph node meta-
stases. Logistic regression analysis showed a
statistically significant effect of both anti-E7\
6-35 positivity and lesion size before treatment
on nodal spread (X2= 13-01; df=2; p=0-0015;
sensitivity 28-2%; specificity 90 5%).
ANTI-E7\6-35 ANTIBODIES AND PROGNOSIS
When the presence of antibodies against E7\
6-35 in pretreatment sera was correlated with
prognosis, a significantly higher prevalence rate
of antibodies against E7\6-35 was found in
patients who ultimately died of disease (32/
105, 30 5%) in comparison with patients who
showed no evidence of disease at the closing
date of the study (35/243, 14-4%, p= 00008).
We performed an analysis of data of 144
patients with stage IB or IIA. Using the Cox
regression model we considered three pre-
treatment prognostic factors (age, lesion size,
and histological grade) which can be de-
termined before surgery, and E7\6-35 positivity
(since the lymph node status cannot be de-
termined before surgery, these data were not
included). The analysis revealed independent
effects of anti-E7\6-35 positivity (p=0 01)
and-to a lesser extent-lesion size (p=0 07)
on survival. Survival curves in relation to anti-
E7\6-35 positivity are shown in the figure.
Statistical analysis of the survival curves (log
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rank test) showed that seropositive stage IB
and IIA patients have a significantly shorter
life expectancy than seronegative patients (p =
00021). A similar difference in survival was
found for all stages taken together (p = 0 0005).
Discussion
Up to now, no data have been available on the
correlation between antibodies against HPV-
16 E7 in pretreatment sera from patients with
cervical carcinoma and tumour or patient re-
lated variables.
An overall prevalence rate of antibodies
against peptide E7\%6-35 of 17-7% was found
in patients with cervical cancer, which was
significantly higher than in the control group
or in patients with cervical intraepithelial neo-
plasia. Similar results have been reported
earlier. Jochmus-Kudielka et al,' using a bac-
terial HPV-16 E7 fusion protein, reported a
prevalence rate of 20-5% in cervical cancer
patients. Krchnak et al,7 using a synthetic pep-
tide comprising amino acids 11 to 30, obtained
a prevalence rate of 24%. Muller et al,9 using
a peptide identical to peptide E7\6-35 in this
study, found a prevalence rate of 37% in HPV-
16 DNA positive cervical cancer patients. Un-
fortunately, no data concerning the presence of
HPV DNA in the tumour tissues were available
from the cervical cancer patients in this study.
When cervical cancer patients were classified
according to stage, a significantly different pre-
valence rate of antibodies against E7\6-35 was
observed between the four FIGO stages, the
highest prevalence being observed in stage IV
patients. Further analysis of the data on anti-
E7 positivity in relation to clinicopathological
indices revealed a significant correlation be-
tween the presence of antibodies against HPV-
16 E7\6-35 in pretreatment sera and a larger
lesion size, dedifferentiation, and lymph node
U-U
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metastasis. After logistic regression analysis
only lesion size and the node status showed an
independent effect on anti-E7 positivity. This
latter finding is in agreement with the data
from Onda et al,'7 which show that lymph node
and distant metastases are more frequent in
antibody positive patients than in antibody neg-
ative patients.
Anti-E7 positivity was also shown to provide
prognostic information. When the prognostic
value of anti-E7 positivity was analysed in ad-
dition to three prognostic indices which can be
determined before therapy (age, lesion size,
and histological grade), only anti-E7 positivity
correlated with poor survival. The prognostic
value of pretreatment anti-E7 positivity may be
explained by the association of anti-E7 pos-
itivity and tumour spread to the regional lymph
nodes, which is a strong indicator of poor
prognosis.
In conclusion, the results of this study show
that the presence of antibodies against E7\6-35
in pretreatment sera from patients with cervical
carcinoma correlates with the size of the lesion,
lymph node involvement, and a worse prog-
nosis. However, since anti-E7\6-35 antibodies
are only detected in a minority of patients with
cervical cancer, the clinical value of detection
of antibodies against E7\6-35 as a tumour
or progression marker is low. The use of E7
antigens resembling the native state, possibly
in combination with E6 antigens, might lead
to assays with greater sensitivity and
specificity.""1819 The results obtained in this
study warrant further studies on the value of
antibodies against E7 as tumour or progression
markers using E7 antigens resembling the nat-
ive state.
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